Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_17c6c7da627b7bead7208250127b52c2 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0058 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-0075 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-12 |
filingDate |
2009-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cbe34805e4c8d913aaa7f2f501931e7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_488cbaebdb93a0c94e4fc9e1f696a1cd |
publicationDate |
2009-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
KR-20090042224-A |
titleOfInvention |
Gene therapy for lung cancer |
abstract |
The present invention relates to a gene therapy agent for lung cancer, specifically using a carboxyl terminal modulator protein (CTMP) as an agent, using a lentivirus as a gene carrier, the efficiency of the lentiviral vector-mediated CTMP and Akt related signals and cells As a result of evaluating the potential effects of Akt1 on cycle regulation, lentiviral-CTMP was delivered to K- ras- depleted lung cancer mice by a nasal inhalation system, which not only significantly inhibited lung tumor development. Aerosol delivery of the lentiviral vector mediated-CTMP was found to be compatible with invasive in vivo gene therapy. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101156091-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011108796-A1 |
priorityDate |
2009-04-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |